TY - JOUR
T1 - Altered cellular metabolism in gliomas — an emerging landscape of actionable co-dependency targets
AU - Bi, Junfeng
AU - Chowdhry, Sudhir
AU - Wu, Sihan
AU - Zhang, Wenjing
AU - Masui, Kenta
AU - Mischel, Paul S.
N1 - Funding Information:
This work was supported by the Ludwig Institute for Cancer Research and by grants from the National Institute for Neurological Diseases and Stroke (NS73831), the Defeat GBM Program of the National Brain Tumour Society, and the Ben and Catherine Ivy Foundation, as well as by an award from the Sharpe/National Brain Tumour Society Research Program and a Compute for the Cure Award from the Nvidia Foundation (to P.S.M.).
Publisher Copyright:
© 2019, Springer Nature Limited.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Altered cellular metabolism is a hallmark of gliomas. Propelled by a set of recent technological advances, new insights into the molecular mechanisms underlying glioma metabolism are rapidly emerging. In this Review, we focus on the dynamic nature of glioma metabolism and how it is shaped by the interaction between tumour genotype and brain microenvironment. Recent advances integrating metabolomics with genomics are discussed, yielding new insight into the mechanisms that drive glioma pathogenesis. Studies that shed light on interactions between the tumour microenvironment and tumour genotype are highlighted, providing important clues as to how gliomas respond to and adapt to their changing tissue and biochemical contexts. Finally, a road map for the discovery of potential new glioma drug targets is suggested, with the goal of translating these new insights about glioma metabolism into clinical benefits for patients.
AB - Altered cellular metabolism is a hallmark of gliomas. Propelled by a set of recent technological advances, new insights into the molecular mechanisms underlying glioma metabolism are rapidly emerging. In this Review, we focus on the dynamic nature of glioma metabolism and how it is shaped by the interaction between tumour genotype and brain microenvironment. Recent advances integrating metabolomics with genomics are discussed, yielding new insight into the mechanisms that drive glioma pathogenesis. Studies that shed light on interactions between the tumour microenvironment and tumour genotype are highlighted, providing important clues as to how gliomas respond to and adapt to their changing tissue and biochemical contexts. Finally, a road map for the discovery of potential new glioma drug targets is suggested, with the goal of translating these new insights about glioma metabolism into clinical benefits for patients.
UR - http://www.scopus.com/inward/record.url?scp=85076082718&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076082718&partnerID=8YFLogxK
U2 - 10.1038/s41568-019-0226-5
DO - 10.1038/s41568-019-0226-5
M3 - Review article
C2 - 31806884
AN - SCOPUS:85076082718
SN - 1474-175X
VL - 20
SP - 57
EP - 70
JO - Nature Reviews Cancer
JF - Nature Reviews Cancer
IS - 1
ER -